Acid Reflux, Heartburn, and Sulfur Burps on a GLP-1 Microdose: Why a Slower Stomach Leaks and Why It Usually Stops

A woman in her forties starts a low weekly dose of semaglutide and, for the first time in years, stops thinking about food between meals. In the third week she notices something else. Dinner sits. Two hours after a normal-sized plate she still feels as if she has just eaten, and when she lies down at eleven there is a burn behind the breastbone and a sour taste that was never there before. Twice in the same week she wakes at three in the morning coughing. And on the mornings after a big omelette or a whey shake, the burps smell of rotten egg. She has not eaten more, or worse. She has eaten the same and it has stayed longer.

Her experience follows the mechanism exactly. GLP-1 receptor agonists slow the stomach's emptying, which is part of why they reduce appetite, and a stomach that empties more slowly stays fuller and under more pressure for hours after a meal. Distension of the stomach is the main trigger for the brief relaxations of the lower oesophageal sphincter that let acid rise, so a fuller stomach for longer means more reflux, especially in the evening and especially lying down. Sulfur burps come from the same delay: protein that would have moved on in an hour now sits for two or three, and bacteria have time to strip the sulfur off it. The labels record both. Reflux disease appears in 5 percent of people on semaglutide 2.4 mg versus 1 percent on placebo, eructation in 7 percent versus 1 percent, and a 2025 cohort study of 24,708 GLP-1 users found 27 percent more reflux diagnoses than in a matched group on a different diabetes drug.

This article covers what the prescribing information and the cohort data report about reflux across the class, the gastric emptying mechanism and why it partly fades, where sulfur burps come from, why weight loss pulls in the opposite direction so that most people end up with less reflux than they started with, what the trials of meal timing, bed elevation, and meal size show, what changes on a microdose, and a table that separates the reflux a smaller dinner fixes from the symptoms that need a clinician.

How common are reflux, heartburn, and burping on a GLP-1 medication?

Reflux and its cousins run at roughly three to five times the placebo rate in the obesity trials, and they appear in every label in the class. The Wegovy prescribing information, which pools the STEP trials of semaglutide 2.4 mg, lists dyspepsia at 9 percent versus 3 percent on placebo, eructation at 7 percent versus 1 percent, abdominal distension at 7 versus 5 percent, flatulence at 6 versus 4 percent, and gastroesophageal reflux disease at 5 percent versus 1 percent. None of these is in the same league as nausea at 44 percent, but reflux disease has the largest ratio over placebo of any gastrointestinal reaction in the table. The Zepbound label for tirzepatide reports dyspepsia at 9 to 10 percent versus 4 percent, eructation at 4 to 5 percent versus 1 percent, and reflux disease at 4 to 5 percent versus 2 percent across the 5, 10, and 15 mg doses. The Ozempic label at diabetes doses records dyspepsia and reflux at lower absolute rates but the same direction.

The trials counted symptoms people volunteered over 68 to 72 weeks, which undercounts mild heartburn that nobody mentions. The cohort data fill the gap. Noh and colleagues published a target trial emulation in Annals of Internal Medicine in 2025 using the UK Clinical Practice Research Datalink: 24,708 adults with type 2 diabetes who started a GLP-1 receptor agonist between 2013 and 2021, compared with 89,096 who started an SGLT-2 inhibitor, followed for a median of three years. New reflux disease diagnoses ran at 7.9 per 1,000 person-years overall, and the GLP-1 group had a 27 percent higher rate than the SGLT-2 group, with complications such as oesophagitis and stricture 55 percent higher. In absolute terms that is 0.7 extra reflux diagnoses per 100 people over three years and 0.8 extra complications per 1,000. Every agent in the class except lixisenatide carried the excess, and the risk of complications was concentrated in people with obesity, smokers, and those with pre-existing stomach conditions.

Two things about those numbers matter for anyone on a protocol. The relative increase is real and consistent across labels and cohorts, and the absolute increase is small: the great majority of people on a GLP-1 medication do not develop reflux disease. What most people experience instead is the milder pattern the labels file under dyspepsia and eructation, a few weeks of post-meal heaviness and burping that the rest of this article is about.

Why does a GLP-1 medication cause reflux?

A GLP-1 medication causes reflux by slowing gastric emptying, so that each meal keeps the stomach fuller, for longer, than the same meal did before. Hjerpsted and colleagues measured this in 2018 in 30 adults with obesity using the paracetamol absorption test, in which the rate a marker appears in the blood tracks how quickly the stomach hands food to the small intestine. After twelve weeks of semaglutide 1.0 mg, the amount absorbed in the first hour after a meal was 27 percent lower than on placebo. The five-hour total was no different, which is the important detail: the stomach still empties everything, it just does the first hour's work over two or three.

That delay matters at the top of the stomach because of how reflux actually happens. The lower oesophageal sphincter is not a leaky valve that acid seeps past. It opens in brief, deliberate relaxations, the same reflex that lets a burp out, and the main trigger for those relaxations is stretch in the upper stomach. Holloway and colleagues showed in 1985 that distending the stomach with a meal or with air multiplied the rate of transient sphincter relaxations and the reflux episodes that rode on them. A stomach that holds a meal for twice as long delivers that stretch signal for twice as long, so there are more openings, and each opening finds a stomach that is still full of acid and food. Lying down removes the help of gravity, which is why the burn arrives at bedtime and the cough at three in the morning.

The delay is not permanent at full strength. Nauck and colleagues showed in 2011 that the gastric emptying effect of a GLP-1 infusion faded sharply within hours of continuous exposure, a phenomenon called tachyphylaxis, and Umapathysivam and colleagues found in 2014 that sustained exposure slowed emptying far less than intermittent exposure. Wharton and colleagues' STEP 1 tolerability analysis fits the same pattern: upper-gut symptoms peaked in the weeks after each dose step and settled between steps. The stomach adapts to a steady level of the drug. What it does not adapt to quickly is a new, higher level, which is why reflux reliably reappears for a fortnight after each escalation.

Where do sulfur burps on a GLP-1 medication come from?

Sulfur burps are hydrogen sulfide gas, and they come from bacteria breaking down the sulfur-containing amino acids in protein that has been sitting too long. Methionine and cysteine are concentrated in eggs, red meat, poultry, fish, whey and casein, and in the allium and cruciferous vegetables such as onion, garlic, broccoli, and cabbage. In a stomach and upper small intestine that hand food along on schedule, most of that protein is broken into amino acids and absorbed before bacteria get much of it. When a GLP-1 medication doubles the time a meal spends in the stomach and slows the small intestine behind it, the bacterial population that lives in the upper gut has hours rather than minutes with a protein-rich substrate, and hydrogen sulfide is the smell of the result. A burp, which is the same sphincter relaxation that lets acid through, carries it up.

The prescribing information counts eructation of any kind, not its smell, so the 7 percent on semaglutide 2.4 mg and the 4 to 5 percent on tirzepatide are the closest published figures. No trial has isolated sulfur burps or tested a remedy for them, and the guidance that follows is inferred from the mechanism rather than measured. Three things reduce the substrate and the time. Spreading protein across smaller portions gives the stomach less to hold at once and keeps the eventual total intact, which matters because protein intake should not fall on a GLP-1 protocol. A two-week trial with less egg, whey, allium, and cruciferous food, then reintroducing them one at a time, identifies whether a particular source is driving the pattern. And a ten to fifteen minute walk after meals speeds gastric emptying modestly in healthy subjects and is the one measure that works on the time side rather than the substrate side.

Sulfur burps that come with repeated vomiting, an inability to keep fluids down, or a swollen tender abdomen belong in a different category and need assessment, since the same slowing that produces the smell can, rarely, progress to the gastric retention and ileus that the labels list as warnings.

Does reflux on a GLP-1 medication get better as weight comes off?

Yes, and for most people the improvement eventually outweighs the cost, because body weight is one of the strongest known drivers of reflux and a GLP-1 protocol removes it. Jacobson and colleagues analysed 10,545 women in the Nurses' Health Study in 2006 and found a clean dose-response: compared with a body mass index of 20 to 22.4, the odds of frequent reflux symptoms were 1.38 at 22.5 to 24.9, 2.20 at 25 to 27.4, 2.92 at 30 to 34.9, and 2.93 above 35. Women who gained more than 3.5 BMI units over the study were 2.8 times more likely to develop frequent symptoms. Pandolfino and colleagues showed the mechanism the same year: abdominal fat raises pressure inside the abdomen and across the junction between stomach and oesophagus, pushing the top of the stomach upward and weakening the seal.

Losing the weight reverses it. Singh and colleagues enrolled 332 adults with overweight or obesity in a structured six-month weight loss programme in 2013 and tracked reflux symptoms alongside weight. The group lost an average of 13 kilograms, and reflux symptoms resolved completely in 65 percent, improved partially in a further 16 percent, and were unchanged in 19 percent, with the size of the improvement tracking the amount of weight lost. Ness-Jensen and colleagues found the same thing in the Norwegian HUNT population in 2013: people who lost more than 3.5 BMI units had roughly double the odds of losing their reflux symptoms, and the effect was strongest in those also taking acid suppression.

So a GLP-1 protocol pulls in two directions at once. In the first month it slows the stomach and reflux gets worse. Over the following months the stomach adapts, and the weight that comes off lowers abdominal pressure and takes reflux with it. The trials measured symptoms people reported at any point in 68 weeks, which is why reflux disease still appears at 5 percent; the cohort measured new diagnoses over three years, which is why the excess is real but small. For the typical person, the worst reflux of the protocol is in weeks two through five, and by the third month there is less of it than before they started.

What reduces reflux on a GLP-1 medication without another prescription?

Four measures with trial support in reflux disease map directly onto a slower stomach: smaller meals, a three-hour gap between dinner and bed, a raised bed head, and a modest-fat evening meal. Meal size comes first because the trigger is stretch. A stomach that empties at half speed reaches the same fullness on half the meal, so the plate that was fine before the protocol now produces the distension that opens the sphincter. Splitting the evening meal in two, or simply stopping when full rather than when the plate is empty, removes most of the trigger. This is the one measure that the medication itself makes easier, since appetite is already lower.

Timing is second. Fujiwara and colleagues surveyed 441 Japanese adults in 2005 and found that a dinner-to-bed interval of under three hours carried an odds ratio of 7.45 for reflux disease compared with four hours or more, the largest single lifestyle association in their analysis. On a GLP-1 medication the interval needs to be at least three hours and arguably longer, because the stomach is still half full at the two-hour mark that would previously have seen it nearly empty. Bed elevation is third. Khan and colleagues randomised 20 people with night-time reflux to a 20 cm bed-head elevation in 2012 and recorded a fall in night-time acid exposure and a fall in symptom scores in the elevated group; Albarqouni and colleagues' 2021 systematic review of five trials found the same direction in each. Pillows do not work, since they bend the waist and raise abdominal pressure; blocks under the bed legs or a wedge under the mattress do. Left-side sleeping reduces acid exposure in small physiological studies because it places the stomach's contents below the junction.

Fat is the fourth. Dietary fat slows gastric emptying on its own and lowers sphincter pressure, so a high-fat dinner on a GLP-1 medication stacks two delays. Keeping the evening meal's fat modest and putting the day's fat earlier is a simple reallocation. Carbonated drinks add gas volume, alcohol relaxes the sphincter and is best avoided in the evening, and the two large evening coffees that many people use to get through the afternoon slump are worth moving earlier. None of these replace the first two measures. Meal size and timing do most of the work.

Is reflux different on a GLP-1 microdose?

Reflux is usually milder on a microdose because the gastric emptying delay scales with dose, and the Zepbound table shows both eructation and reflux disease rising by a percentage point between 5 and 15 mg. A microdose at a quarter to a third of a standard maintenance dose slows the stomach less, so a normal plate produces less distension and fewer sphincter openings. The larger difference, though, is in the escalation. Every full-dose protocol steps the dose up every four weeks for four or five months, and each step reopens the fortnight of upper-gut symptoms that Wharton documented in STEP 1. A microdose protocol that settles at a low level and stays there gives the stomach one adaptation to make rather than five.

Two cautions apply. The Zepbound data show that most of the jump in reflux comes between placebo and the lowest dose, not between low and high, so a microdose reduces the problem without removing it. And anyone who already had reflux before starting carries that baseline into the protocol; the Noh cohort found complications concentrated in people with obesity and pre-existing stomach conditions, who are also the people most likely to be starting a GLP-1 medication. For that group the lifestyle measures above are worth putting in place in week one rather than waiting for the burn. No trial has reported reflux rates at true microdose levels, and the dose-response argument is an inference from the labelled doses.

Which reflux on a GLP-1 medication needs a clinician?

Most reflux on a GLP-1 protocol responds within a week to a smaller evening meal, a three-hour gap before bed, and a raised bed head, and the reflux that survives those for two months is the one to report. Reflux that began sharply with a dose increase is a prescriber question, since holding or stepping back the dose is the usual fix. Difficulty or pain swallowing, food sticking, vomiting blood or material that looks like coffee grounds, black stools, chest pain, or weight loss beyond what the protocol produces are alarm features under every reflux guideline and need same-day assessment; chest pain in particular must never be assumed to be reflux.

Over-the-counter options sit between the two. Antacids work within minutes for an occasional episode. Famotidine before the evening meal suppresses night-time acid for eight to twelve hours and does not interact with an injected GLP-1 medication. The American College of Gastroenterology 2022 guideline recommends an eight-week trial of a once-daily proton pump inhibitor for typical symptoms, then an attempt to stop, and that decision belongs with a prescriber, who may also decide the GLP-1 dose should be held. The table below matches the common patterns to the likely cause and the next step.

The stomach is slower. The meal has to be smaller and earlier.

A GLP-1 receptor agonist holds each meal in the stomach for longer, and a fuller stomach asks the sphincter to open more often. That is the whole of the reflux problem and the whole of the sulfur burp problem. The drug supplies the delay; the meal decides how much there is to hold, how much sulfur is in it, and how close to bedtime it arrives. The labels put reflux disease at 5 percent and the cohort puts the excess at under one case per hundred over three years, which means the typical experience is a few weeks of post-meal heaviness and evening burn that a half-sized dinner, a three-hour gap, and a raised bed head take care of. Underneath, the weight coming off is dismantling the reflux that many people brought to the protocol in the first place. A microdose makes the delay shorter. It does not make the dinner smaller, and that part is still the person's to do.

Frequently asked questions

Clinical references

1. Novo Nordisk. Wegovy (semaglutide) injection 2.4 mg: prescribing information, adverse reactions. US Food and Drug Administration; 2021, with subsequent revisions.
2. Eli Lilly. Zepbound (tirzepatide) injection: prescribing information, adverse reactions. US Food and Drug Administration; 2023, with subsequent revisions.
3. Novo Nordisk. Ozempic (semaglutide) injection: prescribing information, adverse reactions. US Food and Drug Administration; 2017, with subsequent revisions.
4. Noh Y, Yin H, Yu OHY, Azoulay L, et al. Glucagon-like peptide-1 receptor agonists and risk for gastroesophageal reflux disease in patients with type 2 diabetes: a population-based cohort study. Annals of Internal Medicine. 2025;178(9).
5. Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018;20(3):610-619.
6. Holloway RH, Hongo M, Berger K, McCallum RW. Gastric distention: a mechanism for postprandial gastroesophageal reflux. Gastroenterology. 1985;89(4):779-784.
7. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561-1565.
8. Umapathysivam MM, Lee MY, Jones KL, et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes. 2014;63(2):785-790.
9. Halim MA, Degerblad M, Sundbom M, et al. Glucagon-like peptide-1 inhibits prandial gastrointestinal motility through myenteric neuronal mechanisms in humans. Journal of Clinical Endocrinology and Metabolism. 2018;103(2):575-585.
10. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, Obesity and Metabolism. 2022;24(1):94-105.
11. Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA. Body-mass index and symptoms of gastroesophageal reflux in women. New England Journal of Medicine. 2006;354(22):2340-2348.
12. Pandolfino JE, El-Serag HB, Zhang Q, Shah N, Ghosh SK, Kahrilas PJ. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology. 2006;130(3):639-649.
13. Singh M, Lee J, Gupta N, et al. Weight loss can lead to resolution of gastroesophageal reflux disease symptoms: a prospective intervention trial. Obesity. 2013;21(2):284-290.
14. Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Weight loss and reduction in gastroesophageal reflux: a prospective population-based cohort study, the HUNT study. American Journal of Gastroenterology. 2013;108(3):376-382.
15. Fujiwara Y, Machida A, Watanabe Y, et al. Association between dinner-to-bed time and gastro-esophageal reflux disease. American Journal of Gastroenterology. 2005;100(12):2633-2636.
16. Khan BA, Sodhi JS, Zargar SA, et al. Effect of bed head elevation during sleep in symptomatic patients of nocturnal gastroesophageal reflux. Journal of Gastroenterology and Hepatology. 2012;27(6):1078-1082.
17. Albarqouni L, Moynihan R, Clark J, Scott AM, Duggan A, Del Mar C. Head of bed elevation to relieve gastroesophageal reflux symptoms: a systematic review. BMC Family Practice. 2021;22(1):24.
18. Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022;117(1):27-56.